AC Immune マネジメント

マネジメント基準チェック /24

AC Immuneの CEO はAndrea Pfeiferで、 Apr2003年に任命され、の在任期間は 21.58年です。の年間総報酬はCHF 2.65Mで、 21.8%給与と78.2%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の2.45%を直接所有しており、その価値は€ 7.86M 。経営陣と取締役会の平均在任期間はそれぞれ5.8年と6.6年です。

主要情報

Andrea Pfeifer

最高経営責任者

CHF 2.7m

報酬総額

CEO給与比率	21.8%
CEO在任期間	21.6yrs
CEOの所有権	2.4%
経営陣の平均在職期間	5.8yrs
取締役会の平均在任期間	6.6yrs

経営陣の近況

Recent updates

CEO報酬分析

AC Immune の収益と比較して、Andrea Pfeifer の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-CHF 40m
Jun 30 2024	n/a	n/a	-CHF 61m
Mar 31 2024	n/a	n/a	-CHF 55m
Dec 31 2023	CHF 3m	CHF 578k	-CHF 54m
Sep 30 2023	n/a	n/a	-CHF 68m
Jun 30 2023	n/a	n/a	-CHF 67m
Mar 31 2023	n/a	n/a	-CHF 69m
Dec 31 2022	CHF 2m	CHF 558k	-CHF 71m
Sep 30 2022	n/a	n/a	-CHF 73m
Jun 30 2022	n/a	n/a	-CHF 76m
Mar 31 2022	n/a	n/a	-CHF 75m
Dec 31 2021	CHF 2m	CHF 530k	-CHF 73m
Sep 30 2021	n/a	n/a	-CHF 71m
Jun 30 2021	n/a	n/a	-CHF 74m
Mar 31 2021	n/a	n/a	-CHF 71m
Dec 31 2020	CHF 2m	CHF 520k	-CHF 62m
Sep 30 2020	n/a	n/a	-CHF 62m
Jun 30 2020	n/a	n/a	-CHF 25m
Mar 31 2020	n/a	n/a	-CHF 26m
Dec 31 2019	CHF 2m	CHF 510k	CHF 45m
Sep 30 2019	n/a	n/a	CHF 50m
Jun 30 2019	n/a	n/a	CHF 18m
Mar 31 2019	n/a	n/a	CHF 24m
Dec 31 2018	CHF 2m	CHF 455k	-CHF 51m
Sep 30 2018	n/a	n/a	-CHF 32m
Jun 30 2018	n/a	n/a	-CHF 27m
Mar 31 2018	n/a	n/a	-CHF 29m
Dec 31 2017	CHF 2m	CHF 404k	-CHF 26m

報酬と市場: Andreaの総報酬 ($USD 2.96M ) は、 German市場 ($USD 1.03M ) の同規模の企業の平均を上回っています。

報酬と収益: Andreaの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Andrea Pfeifer (67 yo)

21.6yrs

在職期間

CHF 2,650,000

報酬

Prof. Dr. Andrea Pfeifer, Ph.D. has been the Chief Executive Officer of AC Immune SA since 2003. Prof. Dr. Pfeifer Co-founded AC Immune SA in April 2003. She serves as an Advisor and Chairwoman of BioMedPa...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Andrea Pfeifer	Co-Founder	21.6yrs	CHF 2.65m	2.45% € 7.9m
Christopher Roberts	CFO & VP of Finance	2.6yrs	データなし	0.013% € 40.9k
Piergiorgio Donati	Chief Technical Operations Officer	5.8yrs	データなし	0.025% € 79.6k
Jean-Fabien Monin	Chief Administrative Officer	9.3yrs	データなし	0.32% € 1.0m
Howard Donovan	Chief HR Officer	2.6yrs	データなし	0.020% € 65.4k
Madiha Derouazi	Chief Scientific Officer	less than a year	データなし	0.0032% € 10.3k
Gary Waanders	Senior VP of Investor Relations & Corporate Communications	no data	データなし	データなし
Alexandre Caratsch	General Counsel	no data	データなし	データなし
Julian Snow	VP of U.S. Finance & Corporate Development	2.6yrs	データなし	データなし
David Hickman	Head of AD - SME	14.8yrs	データなし	データなし
Joseph Wettstein	Head of Non-AD Proteinopathies & Deputy Chief Scientific Officer	8.8yrs	データなし	データなし
Oliver Sol	VP & Head of Clinical Development	no data	データなし	データなし

5.8yrs

平均在職期間

54.5yo

平均年齢

経験豊富な経営陣: IMRの経営陣は経験豊富で経験豊富です（平均在職期間は5.8年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Andrea Pfeifer	Co-Founder	8.5yrs	CHF 2.65m	2.45% € 7.9m
Jean-Marie Lehn	Chairman of Scientific Advisory Board	no data	データなし	データなし
Claude Nicolau	Member of Scientific Advisory Board	no data	データなし	データなし
Douglas Williams	Independent Non-Executive Chairman	6.6yrs	CHF 179.00k	0.039% € 126.4k
Alf E. Lindberg	Member of Scientific Advisory Board	no data	データなし	データなし
Detlev Riesner	Member of Scientific Advisory Board	no data	CHF 5.00k	データなし
Fred Van Leuven	Member of Scientific Advisory Board	no data	CHF 105.00k	データなし
I. Rosenberg	Member of Scientific Advisory Board	no data	データなし	データなし
M. Monsigny	Member of Scientific Advisory Board	no data	データなし	データなし
E. Lestringant	Member of Scientific Advisory Board	no data	データなし	データなし
Monika Butler	Independent Vice Chair	3.1yrs	CHF 163.00k	0.0092% € 29.7k
Andreas Monsch	Head of Clinical Advisory Board	no data	データなし	データなし

6.6yrs

平均在職期間

74.5yo

平均年齢

経験豊富なボード: IMRの取締役会は経験豊富であると考えられます ( 6.6年の平均在任期間)。

AC Immune マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Insufficient new directors

AC Immune SA, Annual General Meeting, Jun 20, 2024

AC Immune SA Announces the Promotion of Christopher Roberts from Interim Chief Financial Officer to Chief Financial Officer, Effective January 1, 2024

AC Immune SA Announces Executive Changes

AC Immune SA Announces Not Stand for Re-Election of Board of Directors

AC Immune SA, Annual General Meeting, Jun 23, 2023

Recent updates

Ac Immune Reports Positive Interim Results from Phase 2 Trial of Aci-7104.056 Active Immunotherapy in Early Parkinson’S Disease

Insufficient new directors

No longer forecast to breakeven

New minor risk - Profitability

AC Immune SA has filed a Follow-on Equity Offering in the amount of $80 million.

New major risk - Revenue and earnings growth

AC Immune SA, Annual General Meeting, Jun 20, 2024

New minor risk - Profitability

Forecast to breakeven in 2025

Forecast to breakeven in 2026

Full year 2023 earnings released: CHF0.64 loss per share (vs CHF0.85 loss in FY 2022)

New minor risk - Shareholder dilution

AC Immune SA has completed a Follow-on Equity Offering in the amount of $50.05 million.

AC Immune SA has completed a Follow-on Equity Offering in the amount of $50.05 million.

AC Immune SA Announces the Promotion of Christopher Roberts from Interim Chief Financial Officer to Chief Financial Officer, Effective January 1, 2024

New major risk - Revenue and earnings growth

AC Immune SA Announces Executive Changes

AC Immune SA Receives FDA Fast Track Designation for Anti-Amyloid-Beta Active Immunotherapy, ACI-24 060, to Treat Alzheimer's Disease

New major risk - Share price stability

AC Immune SA Announces Not Stand for Re-Election of Board of Directors

AC Immune SA, Annual General Meeting, Jun 23, 2023

AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial

AC Immune’s Alzheimer’s Disease Vaccine-Candidate ACI-35.030 Selected for Further Development

AC Immune SA Opens New Centers in Phase 1b/2 Trial Evaluating ACI-24 Targeting Abeta in Alzheimer’s Disease and Down Syndrome

AC Immune SA Presents Detailed Data from the Phase II Crenezumab Alzheimer’s Prevention Initiative Study in Autosomal Dominant Alzheimer’s Disease Presented At AAIC

AC Immune SA Provides Update on Alzheimer's Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease

AC Immune SA, Annual General Meeting, Jun 24, 2022

AC Immune SA's Anti-Abeta Vaccine Results from Phase 1b Study in Down Syndrome Published in JAMA Neurology

AC Immune SA Announces Executive Changes

AC Immune ACI-35.030 Phase 1b/2a Trial Interim Data Confirm Consistent Safety and Potent Immunogenicity of pTau Alzheimer’s Vaccine in High-dose Cohort

AC Immune ACI-24 Data in Brain Communications Show Abeta Vaccine-Candidate Induces Immunity Against pyroGlu-Abeta, Key Driver of Alzheimer’s Disease

Third quarter 2021 earnings released: CHF0.22 loss per share (vs CHF0.26 loss in 3Q 2020)

AC Immune SA Announces First Positive Cognitive Results for a Tau-Targeting Monoclonal Antibody in Alzheimer’s Disease

AC Immune Provides Update on Alzheimer’s Disease Vaccine Candidates Targeting Pathological Amyloid-Beta

Full year 2020 earnings released: CHF0.86 loss per share (vs CHF0.64 profit in FY 2019)

AC Immune SA Announces New Clinical Results in Down Syndrome and Plans for Future Development of Anti-Amyloid-Beta Vaccine

AC Immune Presents New Preclinical Data for Therapeutic and Diagnostic Candidates Addressing Novel Targets for Neurodegenerative Diseases

AC Immune to Present New Data from Alpha-Synuclein and TDP-43 Programs at the AD/PD™ 2021 Virtual Conference

AC Immune’s Alzheimer’s Vaccine Generates Potent Anti-pTau Antibody Response in a Phase 1b/2a Study

AC Immune SA Initiates Clinical Study of First-in-class Diagnostic for Parkinson’s Disease

New 90-day high: €5.57

Ac Immune Reports Progress for Therapeutic Programs Targeting the Nlrp3 Inflammasome Pathway

New 90-day high: €5.17

AC Immune SA Receives Competitive Target ALS Foundation Grant to Accelerate the Development of Proprietary Phosphorylated TDP-43 Immuno-assay

AC Immune Sa Appoints Carl H. June as Board of Directors

AC Immune SA Hires Johannes R. Streffer as Chief Medical Officer

Revenue beats expectations

Third quarter 2020 earnings released: CHF0.26 loss per share

AC Immune and WuXi Biologics Strengthen Strategic Partnership to Accelerate AC Immune’s Anti-TDP-43 Antibodies into Clinical Development

New 90-day low: €3.83

AC Immune SA Announces EU Grant Supports Collaboration to Accelerate Development of AC Immune's First-in-Class TDP-43 Diagnostic Agent

AC Immune Reports Top Line Results from TAURIEL Phase 2 Trial Evaluating Semorinemab in Early Alzheimer’s Disease

New 90-day low: €4.25

First half earnings released

New 90-day high - €7.95

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24